Chronic Spontaneous Urticaria

Patients with cold urticaria and symptomatic dermographism experienced clinically meaningful and statistically significant complete responses with barzolvolimab, according to a webinar by Celldex Therapeutics.

Sirolimus may be a safe and effective alternative for patients with chronic spontaneous urticaria who do not respond to other treatments, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Patients with chronic spontaneous urticaria experienced early symptom improvements that were sustained through 52 weeks with remibrutinib, according to a presentation at the European Academy of Allergy & Clinical Immunology Congress.

CLEVELAND — For patients with chronic spontaneous urticaria, lab testing can help to phenotype disease and guide treatment, according to James Fernandez, MD, PhD, an allergy and immunology specialist at the Cleveland Clinic.

Incyte and Escient Pharmaceuticals have entered a definitive agreement under which Incyte will acquire Escient for $750 million, the companies announced in a press release.

Incyte has entered into a collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib, the companies announced in a press release.

WASHINGTON — Patients with chronic spontaneous urticaria experienced better quality of life with dupilumab compared with placebo, according to two posters presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

The first patient has been dosed in Jasper Therapeutic’s phase 1b/2a SPOTLIGHT clinical trial of subcutaneous briquilimab for the treatment of chronic inducible urticaria, the company announced in a press release.

Practice owners and directors should familiarize themselves with local and federal employment laws because the penalties for noncompliance can be severe, according to employment lawyer Penelope J. Phillips, JD.